A laboratory team at the Technical University of Dresden has succeeded in developing a zinc-finger-conditioned recombinase that combines the simplicity and targetability of DNA binding domains with the precise DNA editing capability of recombinases.

The use of this novel technology is part of the exclusive license agreement with TU Dresden, which Seamless Therapeutics founders Anne-Kristin Heninger and Felix Lansing have negotiated. This will enable the biotech company to further expand its existing recombinase platform and advance the development of therapeutics.

Statement by Dr. Anne-Kristin Heninger:

"We are excited about the groundbreaking advances in genome editing made by the research team led by Prof. Frank Buchholz at the Faculty of Medicine of the Technical University of Dresden. The fusion of DNA binding domains with the already precise DNA editing capabilities of recombinases expands the possibilities for therapeutic applications for Seamless Therapeutics.

Our goal is to advance the application of programmable recombinases to deliver safe and precise treatments to patients with unmet medical need and make a significant contribution to innovative medicine. The close collaboration with academia and the associated potential for rapid translation of scientific results into practice is an important addition to our work at Seamless."

 Seamless Therapeutics GmbH is supported by the Federal Ministry of Education and Research (BMBF) as part of the "Founding Initiative Biotechnology" (GO-Bio).